CER Daily Newsfeed

Experts Mixed On How Most-Favored-Nation Drug Pricing Would Affect Prices, Access, And Innovation

(2/4, Pragya Kakani, Dhruv Khullar, Emma E. McGinty, Colleen L. Barry, Amelia M. Bond, Health Affairs Forefront) comments “...Experts were conflicted about whether MFN pricing would substantially reduce pharmaceutical innovation benefiting US patients. Thirty-eight percent agreed or strongly agreed that such a policy would reduce innovation, 28 percent disagreed or strongly disagreed, and 32 percent were uncertain. Several panelists suggested that the policy could lead to some decline in innovation because the US represents a large share of global pharmaceutical revenue. However, experts also noted that the effects depend on the magnitude of the decline in global revenues and that reductions in innovation may not be substantial because reductions in revenue are most likely for medications with lower expected returns on investment.” Full

ACOs Improve Primary, Preventive Care Delivery for Medicare Beneficiaries

(2/4, Pearl Steinzor, The American Journal of Managed Care) reports “...Medicare beneficiaries whose physicians participate in accountable care organizations (ACOs), particularly those taking on financial risk for cost and quality, receive substantially more primary and preventive care than beneficiaries outside of these models, according to new data released by Accountable for Health.” Full

EMA Seeks To Improve Regulatory Clarity On Bayesian Methods In Clinical Trials

(2/4, Eliza Slawther, Pink Sheet) reports “...Sponsors are increasingly using Bayesian methods in clinical trials, prompting the European Medicines Agency to evaluate how it can address a lack of ‘clarity’ around when this is acceptable.” Subscription Required